NEW YORK (GenomeWeb News) – NextBio today announced it has forged a multiyear deal with Sanofi for use of the NextBio Clinical platform in the drug manufacturer's R&D work.

Sanofi will use the platform for aggregating, standardizing, and analyzing patient clinical data, next generation sequencing, and other molecular data across public data sources, Sanofi's clinical trials, and Sanofi's hospital partners, NextBio said. Sanofi is using the NextBio Clinical platform as part of its Translational Medicine for Patients program.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.